Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Sehn, Laurie H, Hübel, Kai, Luminari, Stefano · The Lancet · 2026